Barbra Streisand has been making headlines recently due to a now-deleted Instagram comment where she asked Melissa McCarthy if she was taking Ozempic. While this comment raised some eyebrows, Joy Behar from The View has stepped forward to defend the Broadway star.
For those not up to speed, McCarthy posted a photo on April 29 on Instagram showing herself at the Center Theatre Group gala with Hairspray director Adam Shankman. Among the thousands of comments, one from Streisand caught attention: “Give him my regards, did you take Ozempic?”
This seemingly unexpected remark has stirred a lot of discussion online, with fans, critics, and celebrities all chiming in. During a segment on The View, cohost Behar shared her perspective, offering a unique defense of Streisand.
Behar, an 81-year-old host, expressed that she didn’t find asking such a question rude. She even lightened the mood by incorporating a jingle into her commentary.
“If somebody’s lost a lot of weight and you want to know if they’ve taken the drug, you just go, ‘Oh-oh-oh-Ozempic!’ and if they respond, ‘Thank you,’ then that’s the end of the conversation,” Behar remarked.
While Behar defended Streisand’s straightforward inquiry, her cohost Sara Haines observed the culture of discretion surrounding the weight loss drug, Ozempic, which has gained popularity among celebrities.
“In the Hollywood world, it’s like, ‘Who’s your agent?’ These days it’s like, ‘Are you on it? I’m on it. She’s on it!'” Haines noted.
Behar attributed Streisand’s directness to New York’s characteristic lack of sugarcoating, although Haines disagreed, pointing out Behar’s Iowa roots.
Adding to the discussion, cohost Alyssa Farah Griffin defended Streisand, suggesting that as an icon, she can “get away with it.”
Streisand later clarified her comment in an Instagram story, expressing that she simply wanted to pay McCarthy a compliment and forgot about the public nature of social media. McCarthy responded graciously, stating that Streisand is a treasure.
Despite the original post being deleted, the Streisand-McCarthy-Ozempic saga continues to capture attention.
